Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: A controlled study

American Journal of Hypertension

Volumn 25, Issue 6, 2012, Pages 644-650

  Angel, Kristin ^a   Provan, Sella A ^b   Fagerhol, Magne K ^a   Mowinckel, Petter ^b   Kvien, Tore K ^b,c   Atar, Dan ^a,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Anti TNF ; arterial stiffness; blood pressure; carotid intima media thickness; hypertension; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CALGRANULIN; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84861182408     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.12     Document Type: Article

References (31)

1. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-331.
2. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63:522-529.
3. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605. (Pubitemid 44627304)
4. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23:75-80.
5. Mäki-PetäjäKM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, Wilkinson IB. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114:1185-1192. (Pubitemid 44386483)
6. Ferrante A, Giardina AR, Ciccia F, Parrinello G, Licata G, Avellone G, Giardina E, Impastato R, Triolo G. Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. Rheumatol Int 2009; 30:193-198.
7. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55:333-338.
8. Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, Chowienczyk P, Kirkham B. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:1277-1284.
9. Del Porto F, LaganáB, Lai S, Nofroni I, Tinti F, Vitale M, PodestáE, Mitterhofer AP, D'Amelio R. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:1111-1115. (Pubitemid 47050613)
10. Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, Boumpas DT. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38:6-10.
11. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55:150-153. (Pubitemid 43235141)
12. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336:763-765. (Pubitemid 20312185)
13. Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994; 21:733-738. (Pubitemid 24126774)
14. De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, Roth J, De Keyser F. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005; 206:17-27. (Pubitemid 40613430)
15. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, Sakuma M, Shi C, Zago AC, Garasic J, Damokosh AI, Dowie TL, Poisson L, Lillie J, Libby P, Ridker PM, Simon DI. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 113:2278-2284. (Pubitemid 43947973)
16. Altwegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, Corti R, Roffi M, Sütsch G, Gay S, von Eckardstein A, Wischnewsky MB, Lüscher TF, Maier W. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007; 28:941-948. (Pubitemid 47343918)
17. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, Shi C, Sukhova GK, Packard RR, Hogg N, Libby P, Simon DI. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009; 120:427-436.
18. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for selfmeasurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit 2003; 8: 127-133. (Pubitemid 37034568)
19. Brands PJ, Hoeks AP, Willigers J, Willekes C, Reneman RS. An integrated system for the non-invasive assessment of vessel wall and hemodynamic properties of large arteries by means of ultrasound. Eur J Ultrasound 1999; 9:257-266. (Pubitemid 29423394)
20. The Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31:2338-2350.
21. Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47:1203-1207. (Pubitemid 352038227)
22. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:1428-1432. (Pubitemid 41631868)
23. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177:113-118. (Pubitemid 39361145)
24. Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimalmedia thickness as a surrogate for cardiovascular disease events in trials of HMGCoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6:3.
25. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006; 37:1933-1940. (Pubitemid 44297754)
26. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 2006; 22:2181-2190. (Pubitemid 44789983)
27. Boyd JH, Kan B, Roberts H, Wang Y, Walley K. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation and products. Circ res 2008; 102:1239-1246.
28. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13:1042-1049. (Pubitemid 47517513)
29. Larsson PT, Hallerstam S, Rosfors S, Wallén NH. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol 2005; 24:43-51. (Pubitemid 43933048)
30. Kampus P, Kals J, Ristimäe T, Muda P, Ulst K, Zilmer K, Salonen RM, Tuomainen TP, Teesalu R, Zilmer M. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein. J Hypertens 2007; 25:819-825. (Pubitemid 46398877)
31. Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML. Aortic stiffness and carotid intima-media thickness: two independent markers of subclinical vascular damage in young adults? Eur J Clin Invest 2003; 33:949-954. (Pubitemid 37421592)